This announcement is a separate document:
百诚医药：北京海润天睿律师事务所关于杭州百诚医药科技股份有限公司2022年限制性股票激励计划授予价格调整、第一个归属期归属条件成就 及作废部分限制性股票事项的法律意见书
Baicheng Pharmaceutical: Beijing Hairun Tianrui Law Firm\'s legal opinion on price adjustments granted by Hangzhou Baicheng Pharmaceutical Technology Co., Ltd.\'s 2022 restricted stock incentive plan, fulfillment of the conditions for the first period of o
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.